Share chart Laboratory Corporation of America Holdings
About
Laboratory Corporation of America Holdings действует как независимая клиническая лабораторная компания по всему миру. Он работает в двух сегментах: Labcorp Diagnostics (Dx) и Labcorp Drug Development (DD). Он предлагает различные тесты, такие как химический анализ крови, анализ мочи, количество клеток крови, тесты щитовидной железы, мазки Папаниколау, гемоглобин A1C и продукты витамина D, антигены простаты, тесты на венерические заболевания, тесты на гепатит C, микробиологические культуры и процедуры и тесты на алкоголь и другие психоактивные вещества.
More detailsЦена ао | 233.57 |
---|---|
P/E | 17.19 |
P/S | 1.23 |
P/BV | 1.87 |
EV/EBITDA | 10.62 |
Дивиденд ао | 2.88 |
Див.доход ао | 1.34 |
EBITDA | 1.97 |
Сайт | http://www.labcorp.com |
Число акций ао | 0.0876 млрд |
Выручка | 11.55 |
ISIN | US50540R4092 |
Валюта | usd |
IPO date | 1990-03-29 |
Sector | Health Care |
Industry | Health Care Providers & Services |
Валюта отчета | usd |
Change price per day: | 0% (244.26) |
---|---|
Change price per week: | +4.22% (234.38) |
Change price per month: | +12.64% (216.85) |
Change price per 3 month: | +10.36% (221.33) |
Change price per half year: | +14.61% (213.13) |
Change price per year: | +22.76% (198.97) |
Change price per 3 year: | -11.53% (276.08) |
Change price per 5 year: | +38.87% (175.89) |
Change price per 10 year: | +99.01% (122.74) |
Change price per year to date: | +9.03% (224.02) |
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
Dividend, % | Dividend | Result of period | Buy before | Register closing date | Payment before |
---|---|---|---|---|---|
0.31% | 0.72 | II кв. 2024 | 27.08.2024 | 29.08.2024 | 13.09.2024 |
0.35% | 0.72 | I кв. 2024 | 22.05.2024 | 24.05.2024 | 10.06.2024 |
0.34% | 0.72 | IV кв. 2023 | 23.02.2024 | 26.02.2024 | 12.03.2024 |
0.36% | 0.72 | III кв. 2023 | 03.11.2023 | 07.11.2023 | 22.11.2023 |
0.33% | 0.72 | II кв. 2023 | 04.08.2023 | 07.08.2023 | 22.08.2023 |
0.32% | 0.72 | I кв. 2023 | 15.05.2023 | 17.05.2023 | 01.06.2023 |
0.29% | 0.72 | IV кв. 2022 | 20.02.2023 | 22.02.2023 | 09.03.2023 |
0.29% | 0.72 | III кв. 2022 | 14.11.2022 | 16.11.2022 | 01.12.2022 |
0.28% | 0.72 | II кв. 2022 | 15.08.2022 | 17.08.2022 | 01.09.2022 |
0.29% | 0.72 | I кв. 2022 | 16.05.2022 | 18.05.2022 | 02.06.2022 |
Date | Event | |
---|---|---|
25.11.2024 | LH: последний день с дивидендом $0.72 |
Transaction date | Date of disclosure | Insider | Type | Price | Volume | Quantity | Share before, % | Share after, % | Document |
---|---|---|---|---|---|---|---|---|---|
28.03.2024 | 29.03.2024 | van der Vaart Sandra D EVP, Chief Legal Officer |
Sale | 216.74 | 770 077 | 3553 | 0 | 0 | link |
21.02.2024 | 22.02.2024 | DiVincenzo Jonathan P. EVP, Pres, Central Labs & Intl |
Sale | 215.49 | 107 745 | 500 | 0 | 0 | link |
21.02.2024 | 22.02.2024 | EISENBERG GLENN A Chief Financial Officer, EVP |
Sale | 215.97 | 7 451 830 | 34504 | 0 | -0.04 | link |
21.02.2024 | 22.02.2024 | EISENBERG GLENN A Chief Financial Officer, EVP |
Purchase | 163.63 | 2 299 660 | 14054 | 0 | 0.01 | link |
16.02.2022 | 18.02.2022 | NEUPERT PETER M Director |
Purchase | 263.66 | 922 810 | 3500 | 0 | 0 | link |
Institutions | Volume | Share, % |
---|---|---|
Blackrock Inc. | 10488997 | 12.47 |
Vanguard Group Inc | 9745657 | 11.58 |
State Street Corporation | 3770286 | 4.48 |
Wellington Management Group, LLP | 2248093 | 2.67 |
Morgan Stanley | 1934163 | 2.3 |
Geode Capital Management, LLC | 1870479 | 2.22 |
Lazard Asset Management LLC | 1820972 | 2.16 |
JP Morgan Chase & Company | 1511301 | 1.8 |
Dimensional Fund Advisors LP | 1446454 | 1.72 |
Diamond Hill Capital Management Inc | 1423860 | 1.69 |
Head | Job title | Payment | Year of birth |
---|---|---|---|
Mr. Adam H. Schechter | President, CEO & Chairman | 3.72M | 1965 (59 years) |
Mr. Glenn A. Eisenberg | CFO & Executive VP | 1.54M | 1961 (63 years) |
Mr. Mark S. Schroeder | Executive VP, President of Diagnostics Laboratories & COO | 1.06M | 1961 (63 years) |
Mr. Peter J. Wilkinson | Senior VP & Chief Accounting Officer | N/A | 1971 (53 years) |
Mr. Lance V. Berberian | Executive VP and Chief Information & Technology Officer | 876.62k | 1963 (61 year) |
Ms. Amy B. Summy | Executive VP & Chief Marketing Officer | N/A | 1966 (58 years) |
Dr. Brian J. Caveney J.D., M.D., M.P.H. | EVP, President of Early Development Research Laboratories and Chief Medical & Scientific Officer | 1.22M | 1974 (50 years) |
Ms. Anita Z. Graham | Executive VP & Chief Human Resources Officer | 1971 (53 years) | |
Christin O'Donnell | Vice President of Investor Relations | ||
Ms. Sandra D. van der Vaart J.D. | Executive VP, Chief Legal Officer & Corporate Secretary | 1960 (64 years) |
Website: http://www.labcorp.com